Elevai Labs, Inc. Common Stock (ELAB)vsModerna Inc (MRNA)
ELAB
Elevai Labs, Inc. Common Stock
$4.52
-1.74%
HEALTHCARE · Cap: $4.20M
MRNA
Moderna Inc
$143.97
+5.38%
HEALTHCARE · Cap: $56.02B
Smart Verdict
WallStSmart Research — data-driven comparison
Moderna Inc generates 86300% more annual revenue ($2.23B vs $2.58M). ELAB leads profitability with a 0.0% profit margin vs -141.4%. ELAB earns a higher WallStSmart Score of 30/100 (F).
ELAB
Avoid30
out of 100
Grade: F
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ELAB.
Margin of Safety
+70.0%
Fair Value
$134.97
Current Price
$143.97
$9.00 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Trading at 8.5x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ELAB
The strongest argument for ELAB centers on Price/Book.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : ELAB
The primary concerns for ELAB are EPS Growth, Market Cap, Profit Margin.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
ELAB profiles as a value stock while MRNA is a turnaround play — different risk/reward profiles.
MRNA carries more volatility with a beta of 1.11 — expect wider price swings.
MRNA is growing revenue faster at 2.1% — sustainability is the question.
ELAB generates stronger free cash flow (-2M), providing more financial flexibility.
Bottom Line
ELAB scores higher overall (30/100 vs 21/100). MRNA offers better value entry with a 70.0% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Elevai Labs, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
Elevai Labs, Inc. (Ticker: ELAB) is an innovative technology firm at the forefront of artificial intelligence and machine learning, primarily catering to the healthcare and finance sectors. By leveraging sophisticated data analytics, the company empowers organizations to extract actionable insights from intricate datasets, thus enhancing operational efficiencies and supporting strategic decision-making. Positioned strategically within a dynamic technology landscape, Elevai Labs is well-prepared to harness emerging market trends for growth, underscoring its commitment to advancing AI technologies and solidifying its role as a significant player with strong potential for sustainable development and competitive advantage.
Visit Website →Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?